Annual report pursuant to Section 13 and 15(d)
Cover
Document and Entity Information
Financial Statements
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements of Operations
Condensed Consolidated Statement of Changes in Stockholders' Equity
Condensed Consolidated Statements of Cash Flows
Notes to Financial Statements
Organization and Description of Business
Summary of Significant Accounting Policies
Discontinued Operations
Collaboration and Stock Purchase Agreements
Property and Equipment
Fair Value Measurements
Licenses Acquired
Sponsored Research and Clinical Trial Agreements
Intangibles, net
Debt and Interest
Accrued Liabilities and other Long-Term Liabilities
Non-Controlling Interests
Net Loss per Common Share
Stockholders' Equity
Commitments and Contingencies
Employee Benefit Plan
Related Party Transactions
Income taxes
Segment Information
Revenues from Contracts and Significant Customers
Subsequent Events
Accounting Policies
Summary of Significant Accounting Policies (Policies)
Notes Tables
Summary of Significant Accounting Policies (Tables)
Discontinued Operations (Tables)
Collaboration and Stock Purchase Agreements (Tables)
Property and Equipment (Tables)
Fair Value Measurements (Tables)
Licenses Acquired (Tables)
Sponsored Research and Clinical Trial Agreements (Tables)
Intangibles, net (Tables)
Debt and Interest (Tables)
Accrued Liabilities and other Long-Term Liabilities (Tables)
Non-Controlling Interests (Tables)
Net Loss per Common Share (Tables)
Stockholders' Equity (Tables)
Commitments and Contingencies (Tables)
Related Party Transactions (Tables)
Income Taxes (Tables)
Segment Information (Tables)
Revenues from Contracts and Significant Customers (Tables)
Notes Details
Summary of Significant Accounting Policies (Narrative) (Details)
Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)
Discontinued Operations (Narrative) (Details)
Discontinued Operations (Schedule of Cash Flows Statement) (Details)
Collaboration and Stock Purchase Agreements (Narrative) (Details)
Collaboration and Stock Purchase Agreements (Schedule of Assets and Liabilities of Caelum) (Details)
Collaboration and Stock Purchase Agreements (Schedule of Gain from Deconsolidation of Caelum) (Details)
Property and Equipment (Narrative) (Details)
Property and Equipment (Schedule of Property and Equipment) (Details)
Fair Value Measurements (Narrative) (Details)
Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details)
Fair Value Measurements (Fair Value of Liabilities Measured on Recurring Basis) (Details)
Fair Value Measurements (Schedule of Financial Instruments, Measured at Fair Value on a Recurring Basis) (Details)
Fair Value Measurements (Roll Forward of the Changes in Fair Value of Level 3 Financial Instruments) (Details)
Licenses Acquired (Narrative) (Details)
Licenses Acquired (Mustang - Narrative) (Details)
Licenses Acquired (Oncogenuity and Tamid - Narrative) (Details)
Licenses Acquired (Schedule of Research and Development-Licenses) (Details)
Licenses Acquired (Schedule of Research and Development for Licenses Acquired) (Details)
Sponsored Research and Clinical Trial Agreements (Narrative) (Details)
Sponsored Research and Clinical Trial Agreements (Schedule of Research and Development for Sponsored Research and Clinical Trial Agreements) (Details)
Intangibles (Narrative) (Details)
Intangibles (Schedule of Intangible Assets) (Details)
Intangibles (Schedule of JMC Recognized Expense Related to its Product Licenses) (Details)
Intangibles (Schedule of Future Amortization of Intangible Assets) (Details)
Debt and Interest (Narrative) (Details)
Debt and Interest (2018 Venture Notes and Mustang Horizon Notes) (Narrative) (Details)
Debt and Interest (Schedule of Debt) (Details)
Debt and Interest (Interest Expense) (Details)
Accrued Liabilities and other Long-Term Liabilities (Narrative) (Details)
Accrued Liabilities and other Long-Term Liabilities (Schedule of Accrued Expenses and Other Long-Term Liabilities) (Details)
Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)
Net Loss per Common Share (Narrative) (Details)
Net Loss per Common Share (Schedule of Diluted Weighted Average Shares Outstanding) (Details)
Stockholders' Equity (Common Stock and Preferred Stock) (Narrative) (Details)
Stockholders' Equity (Stock Based Compensation) (Narrative) (Details)
Stockholders' Equity (Capital Raise) (Narrative) (Details)
Stockholders' Equity (Stock Based Compensation Plans of Partner Companies) (Details)
Stockholders' Equity (Stock-Based Compensation Expense) (Details)
Stockholders' Equity (Stock Option Activities) (Details)
Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details)
Stockholders' Equity (Schedule of Warrant activities) (Details)
Commitments and Contingencies (Narrative) (Details)
Commitments and Contingencies (Lease Expense) (Details)
Commitments and Contingencies (Quantitative Information about Operating Leases) (Details)
Commitments and Contingencies (Future Minimum Lease Payments) (Details)
Employee Benefit Plan (Narrative) (Details)
Related Party Transactions (Narrative) (Details)
Related Party Transactions (PIK Dividend or Equity Fee Payable) (Details)
Related Party Transactions (Schedule of Equity Fees) (Details)
Related Party Transactions (Management Services Agreement) (Details)
Income Taxes (Narrative) (Details)
Income Taxes (Components of Income Tax Expense (Benefit)) (Details)
Income Taxes (Deferred Tax Assets and Liabilities) (Details)
Income Taxes (Effective Income Tax Rate Reconciliation) (Details)
Segment Information (Narrative) (Details)
Segment Information (Schedule of Segment Information) (Details)
Revenues from Contracts and Significant Customers (Narrative) (Details)
Revenues from Contracts and Significant Customers (Company's product revenue) (Details)
Subsequent Events (Narrative) (Details)
Commitments and Contingencies (Future Minimum Lease Payments) (Details)